Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company based in Bothell, Washington. The company is primarily focused on the development and commercialization of cytisinicline, a plant-based alkaloid designed to treat nicotine dependence. Its clinical programs target both traditional smoking cessation and e-cigarette (vaping) cessation.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Selling, General & Administrative Expenses
31,882
16,252
11,436
10,722
Research & Development Expenses
22,998
22,817
15,814
30,078
Operating Profit
(54,880)
(39,069)
(27,250)
(40,800)
Interest and Investment Income
1,495
2,356
825
199
Interest Expense
(819)
(2,180)
(2,853)
(1,789)
Non-Operating Income
(444)
(934)
(537)
40
Total Non-Operating Income
232
(758)
(2,565)
(1,550)
Income Before Provision for Income Taxes
(54,648)
(39,827)
(29,815)
(42,350)
Consolidated Net Income
(54,648)
(39,827)
(29,815)
(42,350)
Net Income Attributable to Common Shareholders
(54,648)
(39,827)
(29,815)
(42,350)
Basic EPS
-1.25
-1.24
-1.50
-4.00
Diluted EPS
-1.25
-1.24
-1.50
-4.00
Basic Weighted Average Shares Outstanding
43,595
32,071
19,828
10,593
Diluted Weighted Average Shares Outstanding
43,595
32,071
19,828
10,593
Shares Outstanding
53,234
34,685
21,166
17,897
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
20,929
12,753
15,546
24,771
Short-Term Investments
15,475
21,607
—
—
Total Cash and Cash Equivalents
36,404
34,360
15,546
24,771
Other Receivables
—
—
111
105
Total Trade Receivables
—
—
111
105
Other Current Assets
3,485
2,107
1,325
2,454
Total Current Assets
39,889
36,467
16,982
27,330
Net Property, Plant & Equipment
64
119
66
123
Net Intangible Assets
751
974
1,197
1,418
Goodwill
1,034
1,034
1,034
1,034
Other Long-Term Assets
52
39
92
66
Total Assets
41,790
38,633
19,371
29,971
Accounts Payable
867
1,950
618
1,660
Accrued Expenses
2,893
4,677
2,942
3,810
Current Portion of Long-Term Debt
3,765
55
16,725
16,129
Other Current Liabilities
1,557
—
528
—
Total Current Liabilities
9,082
6,682
20,813
21,599
Long-Term Debt
11,185
9,837
6
69
Other Long-Term Liabilities
—
1,149
—
—
Total Long-Term Liabilities
11,185
10,986
6
69
Total Liabilities
20,272
17,734
20,819
21,668
Common Stock
121
103
90
87
Additional Paid-in Capital
281,613
226,343
164,209
144,148
Accumulated Other Comprehensive Income
10
31
4
4
Retained Earnings
(260,226)
(205,578)
(165,751)
(135,936)
Total Common Shareholders' Equity
21,518
20,899
(1,448)
8,303
Total Shareholders' Equity
21,518
20,899
(1,448)
8,303
Total Liabilities and Shareholders' Equity
41,790
38,633
19,371
29,971
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(54,648)
(39,827)
(29,815)
(42,350)
Depreciation & Amortization
228
229
228
236
Share-Based Compensation Expense
8,761
5,325
3,712
3,296
Other Adjustments
460
2,091
2,174
1,170
Changes in Trade Receivables
—
111
(6)
48
Changes in Accounts Payable
(1,083)
1,332
(1,042)
799
Changes in Accrued Expenses
(1,786)
1,735
(848)
168
Changes in Other Operating Activities
(1,397)
(766)
1,118
(936)
Cash from Operating Activities
(49,465)
(29,770)
(24,479)
(37,569)
Capital Expenditure
(3)
—
(21)
—
Purchases of Investments
(24,755)
(47,887)
—
—
Proceeds from Sale of Investments
30,866
26,307
—
—
Other Investing Activities
3
—
—
—
Cash from Investing Activities
6,111
(21,580)
(21)
—
Issuance of Long-Term Debt
5,000
9,814
—
—
Repayments of Long-Term Debt
—
(18,109)
—
—
Net Issuance / (Repayments) of Long-Term Debt
5,000
(8,295)
—
—
Issuance of Common Shares
46,527
56,936
15,498
19,362
Repurchases of Common Shares
—
(114)
(220)
(47)
Net Issuance / (Repurchases) of Common Shares
46,527
56,822
15,278
19,315
Cash from Financing Activities
51,527
48,527
15,278
19,315
Effect of Exchange Rate Changes on Cash and Cash Equivalents
3
—
(3)
3
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash